News

The AHA, Federation of American Hospitals, and American Society of Health-System Pharmacists today convened a panel of experts on Capitol Hill to discuss how continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and staffing investments and identify alternative therapies.

The Food and Drug Administration yesterday updated health care providers about a type of lymphoma

The U.S. District Court for the Western District of Pennsylvania has entered a consent decree prohibiting Ranier’s Rx Laboratory Inc. from manufacturing or distributing compounded drugs until they comply with the Federal Food, Drug, and Cosmetic Act and Food and Drug Administration regulations.

Clinicians can now look up their preliminary eligibility status for the Merit-based Incentive Payment System, one of two payment pathways for clinicians under the Medicare Access and CHIP Reauthorization Act of 2015.

About 29 percent of adults with health insurance last year were underinsured, with high deductibles and out-of-pocket expenses relative to their income.

The AHA's Rural Health Care Leadership Conference wrapped up today with a keynote session on the future of health care.

Sens. Bob Menendez, D-N.J., John Boozman, R-Ark., and Chuck Schumer, D-N.Y., today introduced the Resident Physician Shortage Reduction Act, AHA-supported legislation that would add 15,000 Medicare-funded residency positions over five years to alleviate physician shortages that threaten patients' access to care.

Nearly 50 health care and consumer groups, including the AHA, voiced their support for the Creating and Restoring Equal Access to Equivalent Samples Act as it was reintroduced yesterday in the new Congress.

In his state of the union address last night, President Trump said lowering the cost of health care and prescription drugs and protecting patients with pre-existing conditions were some of his major priorities.

The House Energy and Commerce Health Subcommittee today held a

A witness called for a broad multidisciplinary, multi-strategy approach supported by science and research, similar to the approach used to prevent motor vehicle injuries and death.

Hospitals that serve a disproportionate share of low-income patients were less likely to qualify for financial rewards in the first year of Medicare’s Comprehensive Care for Joint Replacement model.

AHA President and CEO Rick Pollack kicked off today's programming at the AHA Rural Health Care Leadership Conference and moderated a discussion with Erika Rogan, AHA senior associate director of policy, and Travis Robey, AHA senior associate director of federal relations, about what's happening on Capitol Hill and the association's rural advocacy agenda for 2019.

The Senate Health, Education, Labor & Pensions Committee today held a hearing to examine how primary care affects health care costs and outcomes.

The Health Resources and Services Administration's Federal Office of Rural Health Policy plans to award about 75 grants of up to $1 million each to expand opioid and other substance use disorder services in high-risk rural communities.

The authors of a new study on hospital and physician prices “use limited data to draw broad conclusions,” writes AHA Executive Vice President Tom Nickels in the AHA Stat blog.

AHA Board Chairman Brian Gragnolati today kicked off the AHA Rural Health Care Leadership Conference by welcoming more than 900 rural hospital and health system leaders and trustees.

The Centers for Medicare & Medicaid Services and Centers for Disease Control and Prevention today published a proposed rule that would update 1992 proficiency testing and referral requirements.

The Food and Drug Administration Friday warned physicians and patients who use medical devices to monitor levels of the blood thinner warfarin that certain test strips used with the devices may provide inaccurate results and should not be relied on to adjust the drug dosage.

A new study adds to a growing body of literature suggesting that human insulins may result in similar clinical outcomes as higher cost insulin analogues for many patients with type 2 diabetes.